A Comparative, Open-label, Parallel Design, Bioavailability Study of Two Misoprostol Formulations (Angusta™ 25 µg Dispersible Tablets vs. Cytotec® 200 µg Tablets) Following Single Oral or Sublingual Administration and Comparison of Safety of the Two Formulations Following Repeat Dosing Until Labour
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Misoprostol (Primary) ; Misoprostol (Primary)
- Indications Labour induction
- Focus Pharmacokinetics
- 24 Aug 2017 New trial record